X-ZELL Cryoimmunostaining™ technology live in Europe
Brussels, February 2020 – Following the official European launch of X-ZELL’s Cryoimmunostaining™ Suite in November 2019, the Singapore start-up will be holding a series of Live Sessions in 2020 in order to introduce the new technology to some of the leading minds in research, business and politics.
The first Live Sessions tour of 2020 will take place from 10-14 February and focus on Germany, Scandinavia and the BeNeLux region – with the kick-off meeting to be held in Brussels, where the European Commission recently reinforced the EU’s commitment to prevention and early detection.
“We’ve had tremendous success using our Cryoimmunostaining™ technology as part of our own research over the past two years and are now ready to share it with the wider research community,” commented X-ZELL Founder & CEO, Dr Sebastian Bhakdi.
“Nine-colour immunostaining has enabled us to detect a new type of circulating cell that had previously been considered undetectable in clinical routine, which has been nothing short of remarkable.
“It is my absolute pleasure to now be able to personally introduce this world-first technology to my European colleagues and explore how it can help them advance their own research.”
Originally designed to enable X-ZELL’s headline-making research into next-generation biomarkers, X-ZELL’s Cryoimmunostaining™ Suite is the world’s first slide-based, 9-colour immunostaining solution.
Comprised of two patented devices, the X-ZELL Cryoimmunostaining™ Suite enables researchers to stain samples* with up to nine antibodies at a time as compared to an industry high of four to five antibodies, which typically have to be applied in sequence.
The result is the world’s only multiplexed immunostaining system providing a genuine ‘plug & play’ solution – allowing researchers to focus on science instead of optimising the underlying hardware set-up.
Designed & manufactured in Singapore, the X-ZELL Cryoimmunostaining™ Suite will initially be available for Research Use Only.
Researchers interested in trialling the system – as well as learning about X-ZELL’s complete early cancer detection workflow – are encouraged to reach out directly to X-ZELL Founder & CEO, Dr Sebastian Bahdki, via email.
*compatible with suspended cells and cryosections, FFPE version under development. Currently validated for 18 fluorophores and their spectral equivalents, incl. DAPI, BV421, Pacific Blue, Pacific Orange, BV480, PerCp, AF488, PE, PE-Cy5, PE-Cy7, Propidium Iodide, AF594, DRAQ5, AF647, AF750, AF790, AF800, DIR. Please check www.x-zell.com for updates or contact firstname.lastname@example.org
Head of Strategy, Marketing & Communications
+66 6 2197 8788
© 2023 X-ZELL INC